Please login to the form below

Not currently logged in
Email:
Password:

Torisel

This page shows the latest Torisel news and features for those working in and with pharma, biotech and healthcare.

Opdivo cleared for kidney cancer and first-line melanoma

Opdivo cleared for kidney cancer and first-line melanoma

The FDA notes that Opdivo is the first drug to show an improvement in overall survival in RCC since Novartis' Torisel (temsirolimus), which was approved in 2007.

Latest news

  • Getting the GIST

    Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,

  • Extending the arsenal

    Phase I trials are also under way in paediatric patients with recurrent solid tumours, either as a monotherapy or in combination with temsirolimus (Torisel; Pfizer), which is an inhibitor of mTOR,

  • NICE approves Pfizer's kidney cancer drug

    NICE has approved Pfizer's Sutent as a kidney cancer first line treatment, but turned down Roche's Avastin, Bayer's Nexavar and Wyeth's Torisel. ... The body also turned down Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus), despite

  • NICE recommends Sutent

    Sutent was originally reviewed along with Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), and Wyeth's Torisel (temsirolimus) as part of a multiple technology appraisal.

  • Falling Economy

    The four drugs for advanced kidney cancer – Sutent, Nexavar, Avastin and Torisel – could be released from their ban and made available on the NHS for treatment of advanced kidney cancer patients.

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...

Infographics